The global veterinary biologics market is projected to reach USD 3.51 billion by 2030 from USD 2.72 billion in 2025, at a CAGR of 5.2% during the forecast period.
The veterinary biologics market is experiencing significant growth, driven by an expanding companion animal population and rising pet ownership. Increasing concerns about chronic diseases have further boosted demand for veterinary treatments. Government and animal welfare organizations actively promote awareness campaigns, encouraging early diagnosis and treatment of dermatological conditions in both pets and farm animals. Additionally, the growing adoption of pet insurance and high expenditure on animal healthcare support market expansion by improving access to specialized veterinary services. However, the market faces challenges such as the rising cost of pet care, which can limit treatment adoption. Moreover, strict regulatory guidelines and lengthy drug approval processes further restrain market growth.
"The monoclonal antibodies segment has accounted for the largest market share in the veterinary biologics market."
Monoclonal antibodies are projected to experience rapid growth in the veterinary biologics market, driven by their targeted action, high effectiveness, and increasing adoption in livestock health management. These biologics are increasingly used to prevent and treat specific diseases by precisely targeting pathogens or toxins, providing a more selective and effective alternative to traditional therapies like antibiotics. In livestock applications, monoclonal antibodies are especially valuable for conditions that require swift immune support, resulting in decreased morbidity and higher productivity. Their use aligns with the global shift toward sustainable animal farming practices and the reduction of antimicrobial resistance (AMR), making them a preferred choice for advanced biologic treatments.
"The dermatology segment accounted for the largest market share in 2024 in the veterinary biologics market."
The dermatology segment is expected to dominate the veterinary biologics market because of the high prevalence of skin disorders like atopic dermatitis, mange, and flea- or tick-borne skin infections in companion animals. Increasing pet ownership and greater awareness of animal health have boosted demand for advanced dermatological treatments. Biologics, such as monoclonal antibodies, are becoming more popular as effective, targeted therapies with fewer side effects compared to traditional drugs. More approvals of dermatology-focused veterinary biologics, including those targeting chronic skin allergies, further strengthen this segment. Additionally, dermatological issues are among the most common reasons for veterinary visits, ensuring steady demand. Growth in companion animal insurance coverage is also supporting the adoption of high-cost biologics. Overall, these factors position dermatology as the leading segment in the veterinary biologics market.
“North America has accounted for the largest market share in 2024.”
North America held the largest market share in 2024, supported by a well-established veterinary healthcare infrastructure and high pet ownership rates. The region has a strong presence of leading market players investing in research and development for innovative monoclonal antibody therapies. Rising awareness about pet health, along with increasing spending on veterinary care, drives market growth. Additionally, the growing demand for premium pet care products further contributes to North America's dominance in the global veterinary monoclonal antibody industry.
A breakdown of the primary participants referred to for this report is provided below:
• By Company Type: Tier 1–75%, Tier 2–15%, and Tier 3– 10%
• By Designation: C-level–30%, Director-level–23%, and Other Designations–47%
• By Region: North America–35%, Europe–20%, Asia Pacific–25%, Latin America–13%, and Middle East & Africa–7%
The major players operating in the veterinary biologics market are Zoetis (US), Elanco (US), and Merck & Co., Inc. (US).
Research Coverage
This report studies the veterinary biologics market based on animal type, route of administration, product, application, end user, and region. The report also examines factors such as drivers, restraints, opportunities, and challenges that affect market growth. It analyzes the opportunities and challenges within the market and provides details about the competitive landscape for market leaders. Additionally, the report analyzes micro markets in terms of their individual growth trends and forecasts the revenue of market segments across five main regions and their respective countries.
Reasons to Buy the Report
The report can help established firms, as well as new entrants/smaller firms, gauge the pulse of the market, which, in turn, would help them garner a greater share. Firms purchasing the report could use one or a combination of the five strategies mentioned below.
This report provides insights into the following points:
• Analysis of key drivers (Surge in companion animal population and pet ownership. Increasing incidence of infectious zoonotic diseases, Innovations in monoclonal antibodies targeting infectious diseases, Supportive initiatives by government agencies and animal health organization, Growing demand for animal-derived food products), restraints (High cost of veterinary diagnostic tests, Regulatory hurdles and long approval timelines), opportunities (evolving landscape of strategic collaborations and partnerships, untapped growth potential in emerging markets, challenges (Limited Awareness and Shortage of Trained Veterinarians in Low-Income Countries.
• Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and product launches in the veterinary biologics market.
• Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various types of biologic treatments across regions.
• Market Diversification: Exhaustive information about products, untapped regions, recent developments, and investments in the veterinary biologics market.
• Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the veterinary biologics market.
圖表清單 List of Tables & Figures
TABLE 1 VETERINARY BIOLOGICS MARKET: INCLUSIONS & EXCLUSIONS 31
TABLE 2 VETERINARY BIOLOGICS MARKET: STUDY ASSUMPTIONS 45
TABLE 3 VETERINARY BIOLOGICS MARKET: RISK ANALYSIS 46
TABLE 4 PET (DOGS AND CATS) OWNERSHIP AND SPENDING IN US, 2024 58
TABLE 5 MAJOR OUTBREAKS OF ZOONOTIC DISEASES, 2022–2025 59
TABLE 6 PAST AND PROJECTED TRENDS IN MEAT AND MILK CONSUMPTION IN DEVELOPED COUNTRIES, 2002 VS. 2015 VS. 2030 VS. 2050 62
TABLE 7 ASIA: COUNTRY-LEVEL CONSUMPTION OF ANIMAL-DERIVED FOOD PRODUCTS, 2020 VS. 2030 (THOUSAND METRIC TONS) 62
TABLE 8 ASIA: COUNTRY-LEVEL PRODUCTION OF ANIMAL-DERIVED FOOD PRODUCTS,
2020 VS. 2030 (THOUSAND METRIC TONS) 63
TABLE 9 IMPORT DATA FOR HS CODE 300214, BY COUNTRY,
2021–2024 (USD THOUSAND) 72
TABLE 10 EXPORT DATA FOR HS CODE 300214, BY COUNTRY,
2021–2024 (USD THOUSAND) 72
TABLE 11 VETERINARY BIOLOGICS MARKET: PORTER’S FIVE FORCES 73
TABLE 12 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS OF VETERINARY BIOLOGICS, BY END USER 76
TABLE 13 KEY BUYING CRITERIA FOR END USERS 77
TABLE 14 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 77
TABLE 15 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 79
TABLE 16 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 80
TABLE 17 VETERINARY BIOLOGICS MARKET: INNOVATIONS AND PATENT REGISTRATIONS OF VETERINARY MONOCLONAL ANTIBODIES, 2023–2024 83
TABLE 18 INDICATIVE PRICE OF VETERINARY MONOCLONAL ANTIBODIES, BY KEY PLAYER, 2024 (USD) 84
TABLE 19 INDICATIVE SELLING PRICE OF VETERINARY MONOCLONAL ANTIBODIES,
BY REGION, 2022–2024 (USD) 85
TABLE 20 DETAILED LIST OF KEY CONFERENCES & EVENTS IN VETERINARY BIOLOGICS MARKET, JANUARY 2025–DECEMBER 2026 86
TABLE 21 VETERINARY BIOLOGICS MARKET: ROLE IN ECOSYSTEM 88
TABLE 22 UNMET NEEDS IN VETERINARY BIOLOGICS MARKET 89
TABLE 23 KEY COMPANIES IMPLEMENTING AI IN VETERINARY BIOLOGICS MARKET 91
TABLE 24 PIPELINE ANALYSIS IN VETERINARY BIOLOGICS MARKET 93
TABLE 25 US-ADJUSTED RECIPROCAL TARIFF RATES 95
TABLE 26 KEY PRODUCT-RELATED TARIFF EFFECTIVE FOR VETERINARY BIOLOGICS MARKET 95
TABLE 27 IMPACT OF US TARIFFS ON COUNTRIES/REGIONS 96
TABLE 28 VETERINARY BIOLOGICS MARKET, BY PRODUCT TYPE, 2023–2030 (USD MILLION) 98
TABLE 29 LIST OF COMMERCIALLY AVAILABLE MONOCLONAL ANTIBODIES 99
TABLE 30 VETERINARY BIOLOGICS MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD MILLION) 99
TABLE 31 LIST OF USDA-APPROVED IMMUNOGLOBULINS & ANTITOXINS 100
TABLE 32 VETERINARY BIOLOGICS MARKET FOR IMMUNOGLOBULINS & ANTITOXINS,
BY COUNTRY, 2023–2030 (USD MILLION) 101
TABLE 33 VETERINARY BIOLOGICS MARKET FOR IMMUNOMODULATORS & IMMUNOSTIMULANTS, BY COUNTRY, 2023–2030 (USD MILLION) 102
TABLE 34 LIST OF LICENSED VETERINARY DIAGNOSTIC KITS AS APPROVED BY US FDA CENTER FOR VETERINARY BIOLOGICS 103
TABLE 35 VETERINARY BIOLOGICS MARKET FOR DIAGNOSTIC KITS, BY COUNTRY,
2023–2030 (USD MILLION) 105
TABLE 36 VETERINARY BIOLOGICS MARKET, BY ANIMAL TYPE, 2023–2030 (USD MILLION) 107
TABLE 37 COMPANION ANIMALS OWNERSHIP IN US, 2024 107
TABLE 38 VETERINARY BIOLOGICS MARKET FOR COMPANION ANIMALS, BY TYPE,
2023–2030 (USD MILLION) 108
TABLE 39 VETERINARY BIOLOGICS MARKET FOR COMPANION ANIMALS, BY COUNTRY, 2023–2030 (USD MILLION) 108
TABLE 40 KEY PLAYERS PROVIDING VETERINARY BIOLOGICS FOR CANINES 110
TABLE 41 VETERINARY BIOLOGICS MARKET FOR CANINE, BY COUNTRY,
2023–2030 (USD MILLION) 110
TABLE 42 KEY PLAYERS PROVIDING VETERINARY BIOLOGICS FOR FELINES 112
TABLE 43 VETERINARY BIOLOGICS MARKET FOR FELINE, BY COUNTRY,
2023–2030 (USD MILLION) 112
TABLE 44 VETERINARY BIOLOGICS MARKET FOR LIVESTOCK ANIMALS, BY TYPE,
2023–2030 (USD MILLION) 113
TABLE 45 VETERINARY BIOLOGICS MARKET FOR LIVESTOCK ANIMALS, BY COUNTRY,
2023–2030 (USD MILLION) 114
TABLE 46 KEY PLAYERS PROVIDING VETERINARY BIOLOGICS FOR BOVINES 115
TABLE 47 VETERINARY BIOLOGICS MARKET FOR BOVINE, BY COUNTRY,
2023–2030 (USD MILLION) 116
TABLE 48 KEY PLAYERS PROVIDING VETERINARY BIOLOGICS FOR SMALL RUMINANTS 117
TABLE 49 VETERINARY BIOLOGICS MARKET FOR SMALL RUMINANT, BY COUNTRY,
2023–2030 (USD MILLION) 118
TABLE 50 KEY PLAYERS PROVIDING VETERINARY BIOLOGICS FOR PORCINES 119
TABLE 51 VETERINARY BIOLOGICS MARKET FOR PORCINE, BY COUNTRY,
2023–2030 (USD MILLION) 120
TABLE 52 KEY PLAYERS PROVIDING VETERINARY BIOLOGICS FOR POULTRY 121
TABLE 53 VETERINARY BIOLOGICS MARKET FOR POULTRY, BY COUNTRY,
2023–2030 (USD MILLION) 122
TABLE 54 KEY PLAYERS PROVIDING VETERINARY BIOLOGICS FOR EQUINES 123
TABLE 55 VETERINARY BIOLOGICS MARKET FOR EQUINE, BY COUNTRY,
2023–2030 (USD MILLION) 124
TABLE 56 VETERINARY BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION,
2023–2030 (USD MILLION) 126
TABLE 57 VETERINARY BIOLOGICS MARKET FOR INJECTABLE ROUTE OF ADMINISTRATION, BY TYPE, 2023–2030 (USD MILLION) 127
TABLE 58 VETERINARY BIOLOGICS MARKET FOR INJECTABLE ROUTE OF ADMINISTRATION, BY COUNTRY, 2023–2030 (USD MILLION) 127
TABLE 59 VETERINARY BIOLOGICS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2023–2030 (USD MILLION) 129
TABLE 60 VETERINARY BIOLOGICS MARKET FOR INTRAMUSCULAR ROUTE OF ADMINISTRATION, BY COUNTRY, 2023–2030 (USD MILLION) 130
TABLE 61 VETERINARY BIOLOGICS MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2023–2030 (USD MILLION) 132
TABLE 62 VETERINARY BIOLOGICS MARKET FOR OTHER INJECTABLE ROUTES OF ADMINISTRATION, BY COUNTRY, 2023–2030 (USD MILLION) 133
TABLE 63 VETERINARY BIOLOGICS MARKET FOR ORAL ROUTE OF ADMINISTRATION,
BY COUNTRY, 2023–2030 (USD MILLION) 135
TABLE 64 VETERINARY BIOLOGICS MARKET FOR OTHER ROUTES OF ADMINISTRATION,
BY COUNTRY, 2023–2030 (USD MILLION) 136
TABLE 65 VETERINARY BIOLOGICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 139
TABLE 66 VETERINARY BIOLOGICS MARKET FOR DERMATOLOGY, BY COUNTRY,
2023–2030 (USD MILLION) 140
TABLE 67 VETERINARY BIOLOGICS MARKET FOR DIAGNOSTIC TESTNG, BY COUNTRY,
2023–2030 (USD MILLION) 141
TABLE 68 VETERINARY BIOLOGICS MARKET FOR PAIN MANAGEMENT, BY COUNTRY,
2023–2030 (USD MILLION) 143
TABLE 69 VETERINARY BIOLOGICS MARKET FOR INFECTIOUS DISEASE PREVENTION,
BY COUNTRY, 2023–2030 (USD MILLION) 144
TABLE 70 VETERINARY BIOLOGICS MARKET FOR ONCOLOGY, BY COUNTRY,
2023–2030 (USD MILLION) 145
TABLE 71 VETERINARY BIOLOGICS MARKET FOR OTHER APPLICATIONS,BY COUNTRY,
2023–2030 (USD MILLION) 147
TABLE 72 VETERINARY BIOLOGICS MARKET, BY END USER, 2023–2030 (USD MILLION) 149
TABLE 73 AVERAGE TOTAL AMOUNT SPENT PER HOUSEHOLD ON PETS IN US,
2023–2024 (USD) 149
TABLE 74 VETERINARY BIOLOGICS MARKET FOR VETERINARY HOSPITALS & CLINICS,
BY COUNTRY, 2023–2030 (USD MILLION) 150
TABLE 75 VETERINARY BIOLOGICS MARKET FOR VETERINARY DIAGNOSTIC LABS,
BY COUNTRY, 2023–2030 (USD MILLION) 151
TABLE 76 VETERINARY BIOLOGICS MARKET FOR OTHER END USERS, BY COUNTRY,
2023–2030 (USD MILLION) 152
TABLE 77 VETERINARY BIOLOGICS MARKET, BY REGION, 2023–2030 (USD MILLION) 155
TABLE 78 VETERINARY BIOLOGICS MARKET FOR MONOCLONAL ANTIBODIES,
BY REGION, 2023–2030 (THOUSAND UNITS) 155
TABLE 79 NORTH AMERICA: VETERINARY BIOLOGICS MARKET, BY COUNTRY
2023–2030 (USD MILLION 157
TABLE 80 NORTH AMERICA: VETERINARY BIOLOGICS MARKET, BY PRODUCT TYPE,
2023–2030 (USD MILLION) 158
TABLE 81 NORTH AMERICA: VETERINARY BIOLOGICS MARKET, BY ANIMAL TYPE,
2023–2030 (USD MILLION) 158
TABLE 82 NORTH AMERICA: VETERINARY BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 158
TABLE 83 NORTH AMERICA: VETERINARY BIOLOGICS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 159
TABLE 84 NORTH AMERICA: VETERINARY BIOLOGICS MARKET, BY END USER,
2023–2030 (USD MILLION) 159
TABLE 85 US: KEY MACROINDICATORS 160
TABLE 86 US: VETERINARY BIOLOGICS MARKET, BY PRODUCT TYPE,
2023–2030 (USD MILLION) 160
TABLE 87 US: VETERINARY BIOLOGICS MARKET, BY ANIMAL TYPE,
2023–2030 (USD MILLION) 161
TABLE 88 US: VETERINARY BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION,
2023–2030 (USD MILLION) 161
TABLE 89 US: VETERINARY BIOLOGICS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 161
TABLE 90 US: VETERINARY BIOLOGICS MARKET, BY END USER, 2023–2030 (USD MILLION) 162
TABLE 91 CANADA: KEY MACROINDICATORS 163
TABLE 92 CANADA: VETERINARY BIOLOGICS MARKET, BY PRODUCT TYPE,
2023–2030 (USD MILLION) 163
TABLE 93 CANADA: VETERINARY BIOLOGICS MARKET, BY ANIMAL TYPE,
2023–2030 (USD MILLION) 163
TABLE 94 CANADA: VETERINARY BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 164
TABLE 95 CANADA: VETERINARY BIOLOGICS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 164
TABLE 96 CANADA: VETERINARY BIOLOGICS MARKET, BY END USER,
2023–2030 (USD MILLION) 164
TABLE 97 EUROPE: VETERINARY BIOLOGICS MARKET, BY COUNTRY,
2023–2030 (USD MILLION 166
TABLE 98 EUROPE: VETERINARY BIOLOGICS MARKET, BY PRODUCT TYPE,
2023–2030 (USD MILLION) 166
TABLE 99 EUROPE: VETERINARY BIOLOGICS MARKET, BY ANIMAL TYPE,
2023–2030 (USD MILLION) 166
TABLE 100 EUROPE: VETERINARY BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 167
TABLE 101 EUROPE: VETERINARY BIOLOGICS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 167
TABLE 102 EUROPE: VETERINARY BIOLOGICS MARKET, BY END USER,
2023–2030 (USD MILLION) 167
TABLE 103 GERMANY: KEY MACROINDICATORS 168
TABLE 104 GERMANY: VETERINARY BIOLOGICS MARKET, BY PRODUCT TYPE,
2023–2030 (USD MILLION) 168
TABLE 105 GERMANY: VETERINARY BIOLOGICS MARKET, BY ANIMAL TYPE,
2023–2030 (USD MILLION) 169
TABLE 106 GERMANY: VETERINARY BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 169
TABLE 107 GERMANY: VETERINARY BIOLOGICS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 169
TABLE 108 GERMANY: VETERINARY BIOLOGICS MARKET, BY END USER,
2023–2030 (USD MILLION) 170
TABLE 109 UK: KEY MACROINDICATORS 171
TABLE 110 UK: VETERINARY BIOLOGICS MARKET, BY PRODUCT TYPE,
2023–2030 (USD MILLION) 171
TABLE 111 UK: VETERINARY BIOLOGICS MARKET, BY ANIMAL TYPE,
2023–2030 (USD MILLION) 171
TABLE 112 UK: VETERINARY BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION,
2023–2030 (USD MILLION) 172
TABLE 113 UK: VETERINARY BIOLOGICS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 172
TABLE 114 UK: VETERINARY BIOLOGICS MARKET, BY END USER, 2023–2030 (USD MILLION) 172
TABLE 115 FRANCE: KEY MACROINDICATORS 173
TABLE 116 FRANCE: VETERINARY BIOLOGICS MARKET, BY PRODUCT TYPE,
2023–2030 (USD MILLION) 174
TABLE 117 FRANCE: VETERINARY BIOLOGICS MARKET, BY ANIMAL TYPE,
2023–2030 (USD MILLION) 174
TABLE 118 FRANCE: VETERINARY BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 174
TABLE 119 FRANCE: VETERINARY BIOLOGICS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 175
TABLE 120 FRANCE: VETERINARY BIOLOGICS MARKET, BY END USER,
2023–2030 (USD MILLION) 175
TABLE 121 ITALY: KEY MACROINDICATORS 176
TABLE 122 ITALY: VETERINARY BIOLOGICS MARKET, BY PRODUCT TYPE,
2023–2030 (USD MILLION) 176
TABLE 123 ITALY: VETERINARY BIOLOGICS MARKET, BY ANIMAL TYPE,
2023–2030 (USD MILLION) 176
TABLE 124 ITALY: VETERINARY BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION,
2023–2030 (USD MILLION) 177
TABLE 125 ITALY: VETERINARY BIOLOGICS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 177
TABLE 126 ITALY: VETERINARY BIOLOGICS MARKET, BY END USER,
2023–2030 (USD MILLION) 177
TABLE 127 SPAIN: KEY MACROINDICATORS 178
TABLE 128 SPAIN: VETERINARY BIOLOGICS MARKET, BY PRODUCT TYPE,
2023–2030 (USD MILLION) 178
TABLE 129 SPAIN: VETERINARY BIOLOGICS MARKET, BY ANIMAL TYPE,
2023–2030 (USD MILLION) 179
TABLE 130 SPAIN: VETERINARY BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION,
2023–2030 (USD MILLION) 179
TABLE 131 SPAIN: VETERINARY BIOLOGICS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 179
TABLE 132 SPAIN: VETERINARY BIOLOGICS MARKET, BY END USER,
2023–2030 (USD MILLION) 180
TABLE 133 NETHERLANDS: KEY MACROINDICATORS 180
TABLE 134 NETHERLANDS: VETERINARY BIOLOGICS MARKET, BY PRODUCT TYPE,
2023–2030 (USD MILLION) 181
TABLE 135 NETHERLANDS: VETERINARY BIOLOGICS MARKET, BY ANIMAL TYPE,
2023–2030 (USD MILLION) 181
TABLE 136 NETHERLANDS: VETERINARY BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 181
TABLE 137 NETHERLANDS: VETERINARY BIOLOGICS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 182
TABLE 138 NETHERLANDS: VETERINARY BIOLOGICS MARKET, BY END USER,
2023–2030 (USD MILLION) 182
TABLE 139 REST OF EUROPE: VETERINARY BIOLOGICS MARKET, BY PRODUCT TYPE,
2023–2030 (USD MILLION) 183
TABLE 140 REST OF EUROPE: VETERINARY BIOLOGICS MARKET, BY ANIMAL TYPE,
2023–2030 (USD MILLION) 183
TABLE 141 REST OF EUROPE: VETERINARY BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 183
TABLE 142 REST OF EUROPE: VETERINARY BIOLOGICS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 184
TABLE 143 REST OF EUROPE: VETERINARY BIOLOGICS MARKET, BY END USER,
2023–2030 (USD MILLION) 184
TABLE 144 ASIA PACIFIC: VETERINARY BIOLOGICS MARKET, BY COUNTRY
2023–2030 (USD MILLION 185
TABLE 145 ASIA PACIFIC: VETERINARY BIOLOGICS MARKET, BY PRODUCT TYPE,
2023–2030 (USD MILLION) 186
TABLE 146 ASIA PACIFIC: VETERINARY BIOLOGICS MARKET, BY ANIMAL TYPE,
2023–2030 (USD MILLION) 186
TABLE 147 ASIA PACIFIC: VETERINARY BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 186
TABLE 148 ASIA PACIFIC: VETERINARY BIOLOGICS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 187
TABLE 149 ASIA PACIFIC: VETERINARY BIOLOGICS MARKET, BY END USER,
2023–2030 (USD MILLION) 187
TABLE 150 JAPAN: KEY MACROINDICATORS 188
TABLE 151 JAPAN: VETERINARY BIOLOGICS MARKET, BY PRODUCT TYPE,
2023–2030 (USD MILLION) 188
TABLE 152 JAPAN: VETERINARY BIOLOGICS MARKET, BY ANIMAL TYPE,
2023–2030 (USD MILLION) 189
TABLE 153 JAPAN: VETERINARY BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION,
2023–2030 (USD MILLION) 189
TABLE 154 JAPAN: VETERINARY BIOLOGICS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 189
TABLE 155 JAPAN: VETERINARY BIOLOGICS MARKET, BY END USER,
2023–2030 (USD MILLION) 190
TABLE 156 CHINA: KEY MACROINDICATORS 191
TABLE 157 CHINA: VETERINARY BIOLOGICS MARKET, BY PRODUCT TYPE,
2023–2030 (USD MILLION) 191
TABLE 158 CHINA: VETERINARY BIOLOGICS MARKET, BY ANIMAL TYPE,
2023–2030 (USD MILLION) 191
TABLE 159 CHINA: VETERINARY BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION,
2023–2030 (USD MILLION) 192
TABLE 160 CHINA: VETERINARY BIOLOGICS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 192
TABLE 161 CHINA: VETERINARY BIOLOGICS MARKET, BY END USER,
2023–2030 (USD MILLION) 192
TABLE 162 INDIA: PRODUCTION AND CONSUMPTION OF ANIMAL-DERIVED FOOD PRODUCTS, 2000 VS. 2030 (THOUSAND METRIC TONS) 194
TABLE 163 INDIA: KEY MACROINDICATORS 194
TABLE 164 INDIA: VETERINARY BIOLOGICS MARKET, BY PRODUCT TYPE,
2023–2030 (USD MILLION) 194
TABLE 165 INDIA: VETERINARY BIOLOGICS MARKET, BY ANIMAL TYPE,
2023–2030 (USD MILLION) 195
TABLE 166 INDIA: VETERINARY BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION,
2023–2030 (USD MILLION) 195
TABLE 167 INDIA: VETERINARY BIOLOGICS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 195
TABLE 168 INDIA: VETERINARY BIOLOGICS MARKET, BY END USER,
2023–2030 (USD MILLION) 196
TABLE 169 AUSTRALIA: KEY MACROINDICATORS 196
TABLE 170 AUSTRALIA: VETERINARY BIOLOGICS MARKET, BY PRODUCT TYPE,
2023–2030 (USD MILLION) 197
TABLE 171 AUSTRALIA: VETERINARY BIOLOGICS MARKET, BY ANIMAL TYPE,
2023–2030 (USD MILLION) 197
TABLE 172 AUSTRALIA: VETERINARY BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 197
TABLE 173 AUSTRALIA: VETERINARY BIOLOGICS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 198
TABLE 174 AUSTRALIA: VETERINARY BIOLOGICS MARKET, BY END USER,
2023–2030 (USD MILLION) 198
TABLE 175 SOUTH KOREA: KEY MACROINDICATORS 199
TABLE 176 SOUTH KOREA: VETERINARY BIOLOGICS MARKET, BY PRODUCT TYPE,
2023–2030 (USD MILLION) 199
TABLE 177 SOUTH KOREA: VETERINARY BIOLOGICS MARKET, BY ANIMAL TYPE,
2023–2030 (USD MILLION) 199
TABLE 178 SOUTH KOREA: VETERINARY BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 200
TABLE 179 SOUTH KOREA: VETERINARY BIOLOGICS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 200
TABLE 180 SOUTH KOREA: VETERINARY BIOLOGICS MARKET, BY END USER,
2023–2030 (USD MILLION) 201
TABLE 181 NEW ZEALAND: KEY MACROINDICATORS 201
TABLE 182 NEW ZEALAND: VETERINARY BIOLOGICS MARKET, BY PRODUCT TYPE,
2023–2030 (USD MILLION) 202
TABLE 183 NEW ZEALAND: VETERINARY BIOLOGICS MARKET, BY ANIMAL TYPE,
2023–2030 (USD MILLION) 202
TABLE 184 NEW ZEALAND: VETERINARY BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 202
TABLE 185 NEW ZEALAND: VETERINARY BIOLOGICS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 203
TABLE 186 NEW ZEALAND: VETERINARY BIOLOGICS MARKET, BY END USER,
2023–2030 (USD MILLION) 203
TABLE 187 REST OF ASIA PACIFIC: VETERINARY BIOLOGICS MARKET, BY PRODUCT TYPE, 2023–2030 (USD MILLION) 204
TABLE 188 REST OF ASIA PACIFIC: VETERINARY BIOLOGICS MARKET, BY ANIMAL TYPE,
2023–2030 (USD MILLION) 204
TABLE 189 REST OF ASIA PACIFIC: VETERINARY BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 204
TABLE 190 REST OF ASIA PACIFIC: VETERINARY BIOLOGICS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 205
TABLE 191 REST OF ASIA PACIFIC: VETERINARY BIOLOGICS MARKET, BY END USER,
2023–2030 (USD MILLION) 205
TABLE 192 LATIN AMERICA: VETERINARY BIOLOGICS MARKET, BY COUNTRY,
2023–2030 (USD MILLION 206
TABLE 193 LATIN AMERICA: VETERINARY BIOLOGICS MARKET, BY PRODUCT TYPE,
2023–2030 (USD MILLION) 206
TABLE 194 LATIN AMERICA: VETERINARY BIOLOGICS MARKET, BY ANIMAL TYPE,
2023–2030 (USD MILLION) 207
TABLE 195 LATIN AMERICA: VETERINARY BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 207
TABLE 196 LATIN AMERICA: VETERINARY BIOLOGICS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 208
TABLE 197 LATIN AMERICA: VETERINARY BIOLOGICS MARKET, BY END USER,
2023–2030 (USD MILLION) 208
TABLE 198 BRAZIL: KEY MACROINDICATORS 209
TABLE 199 BRAZIL: VETERINARY BIOLOGICS MARKET, BY PRODUCT TYPE,
2023–2030 (USD MILLION) 209
TABLE 200 BRAZIL: VETERINARY BIOLOGICS MARKET, BY ANIMAL TYPE,
2023–2030 (USD MILLION) 209
TABLE 201 BRAZIL: VETERINARY BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION,
2023–2030 (USD MILLION) 210
TABLE 202 BRAZIL: VETERINARY BIOLOGICS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 210
TABLE 203 BRAZIL: VETERINARY BIOLOGICS MARKET, BY END USER,
2023–2030 (USD MILLION) 210
TABLE 204 MEXICO: KEY MACROINDICATORS 211
TABLE 205 MEXICO: VETERINARY BIOLOGICS MARKET, BY PRODUCT TYPE,
2023–2030 (USD MILLION) 211
TABLE 206 MEXICO: VETERINARY BIOLOGICS MARKET, BY ANIMAL TYPE,
2023–2030 (USD MILLION) 212
TABLE 207 MEXICO: VETERINARY BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 212
TABLE 208 MEXICO: VETERINARY BIOLOGICS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 212
TABLE 209 MEXICO: VETERINARY BIOLOGICS MARKET, BY END USER,
2023–2030 (USD MILLION) 213
TABLE 210 REST OF LATIN AMERICA: VETERINARY BIOLOGICS MARKET, BY PRODUCT TYPE, 2023–2030 (USD MILLION) 213
TABLE 211 REST OF LATIN AMERICA: VETERINARY BIOLOGICS MARKET, BY ANIMAL TYPE, 2023–2030 (USD MILLION) 214
TABLE 212 REST OF LATIN AMERICA: VETERINARY BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 214
TABLE 213 REST OF LATIN AMERICA: VETERINARY BIOLOGICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 214
TABLE 214 REST OF LATIN AMERICA: VETERINARY BIOLOGICS MARKET, BY END USER,
2023–2030 (USD MILLION) 215
TABLE 215 MIDDLE EAST & AFRICA: VETERINARY BIOLOGICS MARKET, BY REGION,
2023–2030 (USD MILLION) 216
TABLE 216 MIDDLE EAST & AFRICA: VETERINARY BIOLOGICS MARKET, BY PRODUCT TYPE, 2023–2030 (USD MILLION) 216
TABLE 217 MIDDLE EAST & AFRICA: VETERINARY BIOLOGICS MARKET, BY ANIMAL TYPE, 2023–2030 (USD MILLION) 216
TABLE 218 MIDDLE EAST & AFRICA: VETERINARY BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 217
TABLE 219 MIDDLE EAST & AFRICA: VETERINARY BIOLOGICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 217
TABLE 220 MIDDLE EAST & AFRICA: VETERINARY BIOLOGICS MARKET, BY END USER,
2023–2030 (USD MILLION) 218
TABLE 221 GCC COUNTRIES: VETERINARY BIOLOGICS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 218
TABLE 222 GCC COUNTRIES: VETERINARY BIOLOGICS MARKET, BY PRODUCT TYPE,
2023–2030 (USD MILLION) 219
TABLE 223 GCC COUNTRIES: VETERINARY BIOLOGICS MARKET, BY ANIMAL TYPE,
2023–2030 (USD MILLION) 219
TABLE 224 GCC COUNTRIES: VETERINARY BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 219
TABLE 225 GCC COUNTRIES: VETERINARY BIOLOGICS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 220
TABLE 226 GCC COUNTRIES: VETERINARY BIOLOGICS MARKET, BY END USER,
2023–2030 (USD MILLION) 220
TABLE 227 KINGDOM OF SAUDI ARABIA: KEY MACROINDICATORS 221
TABLE 228 KINGDOM OF SAUDI ARABIA (KSA): VETERINARY BIOLOGICS MARKET,
BY PRODUCT TYPE, 2023–2030 (USD MILLION) 221
TABLE 229 KINGDOM OF SAUDI ARABIA (KSA): VETERINARY BIOLOGICS MARKET,
BY ANIMAL TYPE, 2023–2030 (USD MILLION) 221
TABLE 230 KINGDOM OF SAUDI ARABIA (KSA): VETERINARY BIOLOGICS MARKET,
BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 222
TABLE 231 KINGDOM OF SAUDI ARABIA (KSA): VETERINARY BIOLOGICS MARKET,
BY APPLICATION, 2023–2030 (USD MILLION) 222
TABLE 232 KINGDOM OF SAUDI ARABIA (KSA): VETERINARY BIOLOGICS MARKET,
BY END USER, 2023–2030 (USD MILLION) 223
TABLE 233 UNITED ARAB EMIRATES (UAE): KEY MACROINDICATORS 223
TABLE 234 UNITED ARAB EMIRATES (UAE): VETERINARY BIOLOGICS MARKET,
BY PRODUCT TYPE, 2023–2030 (USD MILLION) 224
TABLE 235 UNITED ARAB EMIRATES (UAE): VETERINARY BIOLOGICS MARKET, BY ANIMAL TYPE, 2023–2030 (USD MILLION) 224
TABLE 236 UNITED ARAB EMIRATES (UAE): VETERINARY BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 224
TABLE 237 UNITED ARAB EMIRATES (UAE): VETERINARY BIOLOGICS MARKET,
BY APPLICATION, 2023–2030 (USD MILLION) 225
TABLE 238 UNITED ARAB EMIRATES (UAE): VETERINARY BIOLOGICS MARKET,
BY END USER, 2023–2030 (USD MILLION) 225
TABLE 239 REST OF GCC COUNTRIES: VETERINARY BIOLOGICS MARKET, BY PRODUCT TYPE, 2023–2030 (USD MILLION) 226
TABLE 240 REST OF GCC COUNTRIES: VETERINARY BIOLOGICS MARKET, BY ANIMAL TYPE, 2023–2030 (USD MILLION) 226
TABLE 241 REST OF GCC COUNTRIES: VETERINARY BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 226
TABLE 242 REST OF GCC COUNTRIES: VETERINARY BIOLOGICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 227
TABLE 243 REST OF GCC COUNTRIES: VETERINARY BIOLOGICS MARKET, BY END USER, 2023–2030 (USD MILLION) 227
TABLE 244 REST OF MIDDLE EAST & AFRICA: VETERINARY BIOLOGICS MARKET,
BY PRODUCT TYPE, 2023–2030 (USD MILLION) 228
TABLE 245 REST OF MIDDLE EAST & AFRICA: VETERINARY BIOLOGICS MARKET,
BY ANIMAL TYPE, 2023–2030 (USD MILLION) 228
TABLE 246 REST OF MIDDLE EAST & AFRICA: VETERINARY BIOLOGICS MARKET,
BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 228
TABLE 247 REST OF MIDDLE EAST & AFRICA: VETERINARY BIOLOGICS MARKET,
BY APPLICATION, 2023–2030 (USD MILLION) 229
TABLE 248 REST OF MIDDLE EAST & AFRICA: VETERINARY BIOLOGICS MARKET,
BY END USER, 2023–2030 (USD MILLION) 229
TABLE 249 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN VETERINARY BIOLOGICS MARKET 230
TABLE 250 VETERINARY BIOLOGICS MARKET: DEGREE OF COMPETITION, 2024 233
TABLE 251 VETERINARY BIOLOGICS MARKET: DEGREE OF COMPETITION, 2024 234
TABLE 252 VETERINARY DIAGNOSTIC KITS MARKET: DEGREE OF COMPETITION, 2024 237
TABLE 254 VETERINARY BIOLOGICS MARKET: REGION FOOTPRINT 242
TABLE 255 VETERINARY BIOLOGICS MARKET: PRODUCT TYPE FOOTPRINT 243
TABLE 256 VETERINARY BIOLOGICS MARKET: ANIMAL TYPE FOOTPRINT 244
TABLE 257 VETERINARY BIOLOGICS MARKET: APPLICATION FOOTPRINT 245
TABLE 258 VETERINARY BIOLOGICS MARKET: DETAILED LIST OF KEY STARTUP/SME PLAYERS 248
TABLE 259 VETERINARY BIOLOGICS MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SME PLAYERS, BY ANIMAL TYPE AND REGION 249
TABLE 260 VETERINARY BIOLOGICS MARKET: PRODUCT LAUNCHES & APPROVALS,
JANUARY 2022–AUGUST 2025 252
TABLE 261 VETERINARY BIOLOGICS MARKET: DEALS, JANUARY 2022–AUGUST 2025 253
TABLE 262 VETERINARY BIOLOGICS MARKET: EXPANSIONS, JANUARY 2022–AUGUST 2025 254
TABLE 263 VETERINARY BIOLOGICS MARKET: OTHER DEVELOPMENTS,
JANUARY 2022–AUGUST 2025 255
TABLE 264 ZOETIS SERVICES LLC: COMPANY OVERVIEW 256
TABLE 265 ZOETIS SERVICES LLC: PRODUCTS OFFERED 257
TABLE 266 ZOETIS SERVICES LLC: PRODUCT LAUNCHES & APPROVALS,
JANUARY 2022–AUGUST 2025 259
TABLE 267 ZOETIS SERVICES LLC: DEALS, JANUARY 2022–AUGUST 2025 260
TABLE 268 ZOETIS SERVICES LLC: EXPANSIONS, JANUARY 2022–AUGUST 2025 260
TABLE 269 ZOETIS SERVICES LLC: OTHER DEVELOPMENTS, JANUARY 2022–AUGUST 2025 261
TABLE 270 IDEXX: COMPANY OVERVIEW 262
TABLE 271 IDEXX: PRODUCTS OFFERED 263
TABLE 272 IDEXX: PRODUCT LAUNCHES, JANUARY 2022–AUGUST 2025 267
TABLE 273 ELANCO: COMPANY OVERVIEW 269
TABLE 274 ELANCO: PRODUCTS OFFERED 270
TABLE 275 ELANCO: PRODUCT LAUNCHES, JANUARY 2022–AUGUST 2025 271
TABLE 276 ELANCO: DEALS, JANUARY 2022–AUGUST 2025 271
TABLE 277 ELANCO: EXPANSIONS, JANUARY 2022−AUGUST 2025 272
TABLE 278 MERCK & CO., INC.: COMPANY OVERVIEW 273
TABLE 279 MERCK & CO., INC.: PRODUCTS OFFERED 274
TABLE 280 MERCK & CO., INC.: PRODUCT LAUNCHES, JANUARY 2022−AUGUST 2025 275
TABLE 281 MERCK & CO., INC.: EXPANSIONS, JANUARY 2022−AUGUST 2025 275
TABLE 282 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 277
TABLE 283 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED 278
TABLE 284 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY OVERVIEW 280
TABLE 285 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: PRODUCTS OFFERED 281
TABLE 286 BOEHRINGER INGELHEIM INTERNATIONAL GMBH:
DEALS, JANUARY 2022–AUGUST 2025 282
TABLE 287 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: EXPANSIONS,
JANUARY 2022–AUGUST 2025 282
TABLE 288 NEOGEN CORPORATION: COMPANY OVERVIEW 283
TABLE 289 NEOGEN CORPORATION: PRODUCTS OFFERED 284
TABLE 290 NEOGEN CORPORATION: DEALS, JANUARY 2022–AUGUST 2025 285
TABLE 291 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW 286
TABLE 292 BIO-RAD LABORATORIES, INC.: PRODUCTS OFFERED 287
TABLE 293 IMMUCELL CORPORATION: COMPANY OVERVIEW 288
TABLE 294 IMMUCELL CORPORATION: PRODUCTS OFFERED 289
TABLE 295 IMMUCELL CORPORATION: OTHER DEVELOPMENTS,
JANUARY 2022–AUGUST 2025 290
TABLE 296 INNOVATIVE DIAGNOSTICS: COMPANY OVERVIEW 291
TABLE 297 INNOVATIVE DIAGNOSTICS: PRODUCTS OFFERED 291
TABLE 298 BIONOTE USA INC.: COMPANY OVERVIEW 295
TABLE 299 BIOCHECK: COMPANY OVERVIEW 296
TABLE 300 PLASVACC USA: COMPANY OVERVIEW 297
TABLE 301 NOVAVIVE INC.: COMPANY OVERVIEW 298
TABLE 302 MG BIOLOGICS: COMPANY OVERVIEW 299
TABLE 303 STALLERGENES GREER: COMPANY OVERVIEW 300
TABLE 304 BIOSTONE ANIMAL HEALTH: COMPANY OVERVIEW 301
TABLE 305 COLORADO SERUM COMPANY: COMPANY OVERVIEW 302
TABLE 306 PADULA SERUMS PTY LTD.: COMPANY OVERVIEW 303
TABLE 307 LAKE IMMUNOGENICS: COMPANY OVERVIEW 304
TABLE 308 INBIOS INTERNATIONAL, INC.: COMPANY OVERVIEW 304
TABLE 309 PRINCETON BIOMEDITECH CORPORATION: COMPANY OVERVIEW 305
TABLE 310 TETRACORE, INC.: COMPANY OVERVIEW 306
TABLE 311 VMRD, INC.: COMPANY OVERVIEW 307
TABLE 312 ANIMAB: COMPANY OVERVIEW 308
FIGURE 1 VETERINARY BIOLOGICS MARKET SEGMENTATION & REGIONAL SCOPE 30
FIGURE 2 VETERINARY BIOLOGICS MARKET: YEARS CONSIDERED 32
FIGURE 3 VETERINARY BIOLOGICS MARKET: RESEARCH DESIGN 33
FIGURE 4 VETERINARY BIOLOGICS MARKET: KEY DATA FROM SECONDARY SOURCES 35
FIGURE 5 VETERINARY BIOLOGICS MARKET: KEY PRIMARY SOURCES 36
FIGURE 6 VETERINARY BIOLOGICS MARKET: INSIGHTS FROM KEY PRIMARIES 37
FIGURE 7 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY- AND DEMAND-SIDE PARTICIPANTS 37
FIGURE 8 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE):
BY COMPANY TYPE, DESIGNATION, AND REGION 38
FIGURE 9 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY END USER, DESIGNATION, AND REGION 38
FIGURE 10 VETERINARY BIOLOGICS MARKET SIZE ESTIMATION:
SUPPLY-SIDE ANALYSIS (2024) 39
FIGURE 11 VETERINARY BIOLOGICS MARKET SIZE ESTIMATION 40
FIGURE 12 VETERINARY BIOLOGICS MARKET: TOP-DOWN APPROACH 41
FIGURE 13 VETERINARY BIOLOGICS MARKET: BOTTOM-UP APPROACH 42
FIGURE 14 VETERINARY BIOLOGICS MARKET: CAGR PROJECTIONS 43
FIGURE 15 VETERINARY BIOLOGICS MARKET: DATA TRIANGULATION METHODOLOGY 44
FIGURE 16 VETERINARY BIOLOGICS MARKET, BY PRODUCT TYPE,
2025 VS. 2030 (USD MILLION) 47
FIGURE 17 VETERINARY BIOLOGICS MARKET, BY ANIMAL TYPE,
2025 VS. 2030 (USD MILLION) 48
FIGURE 18 VETERINARY BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION,
2025 VS. 2030 (USD MILLION) 48
FIGURE 19 VETERINARY BIOLOGICS MARKET, BY APPLICATION, 2025 VS. 2030 (USD MILLION) 49
FIGURE 20 VETERINARY BIOLOGICS MARKET, BY END USER, 2025 VS. 2030 (USD MILLION) 50
FIGURE 21 GEOGRAPHICAL SNAPSHOT OF VETERINARY BIOLOGICS MARKET 51
FIGURE 22 INCREASING PREVALENCE OF CHRONIC DISEASES AMONG COMPANION ANIMALS TO DRIVE MARKET 52
FIGURE 23 US AND COMPANION ANIMALS COMMANDED LARGEST NORTH AMERICAN VETERINARY BIOLOGICS MARKET SHARE IN 2024 53
FIGURE 24 MONOCLONAL ANTIBODIES CAPTURED LARGEST SHARE DURING FORECAST PERIOD 53
FIGURE 25 COMPANION ANIMALS TO ACCOUNT FOR LARGEST MARKET SHARE IN 2030 54
FIGURE 26 INJECTABLE ROUTE OF ADMINISTRATION TO DOMINATE MARKET IN 2030 54
FIGURE 27 DERMATOLOGY TO LEAD VETERINARY BIOLOGICS MARKET IN 2030 55
FIGURE 28 US TO REGISTER HIGHEST GROWTH IN VETERINARY BIOLOGICS MARKET
FROM 2025 TO 2030 56
FIGURE 29 VETERINARY BIOLOGICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES,
AND CHALLENGES 57
FIGURE 30 VETERINARY BIOLOGICS MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 70
FIGURE 31 VETERINARY BIOLOGICS MARKET: VALUE CHAIN ANALYSIS 71
FIGURE 32 VETERINARY BIOLOGICS MARKET: PORTER’S FIVE FORCES ANALYSIS 73
FIGURE 33 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY END USER 75
FIGURE 34 KEY BUYING CRITERIA FOR MAJOR END USERS 76
FIGURE 35 PATENT ANALYSIS FOR VETERINARY MONOCLONAL ANTIBODIES IN VETERINARY BIOLOGICS MARKET, JANUARY 2014–AUGUST 2025 82
FIGURE 36 TOP APPLICANT COUNTRIES AND NUMBER OF PATENT APPLICANTS FOR VETERINARY MONOCLONAL ANTIBODIES, BY JURISDICTION,
JANUARY 2014–AUGUST 2025 83
FIGURE 37 VETERINARY BIOLOGICS MARKET: ECOSYSTEM ANALYSIS 87
FIGURE 38 KEY AI USE CASES IN VETERINARY BIOLOGICS MARKET 91
FIGURE 39 FUNDING AND NUMBER OF DEALS IN VETERINARY BIOLOGICS MARKET,
2020–2024 (USD MILLION) 92
FIGURE 40 NORTH AMERICA: VETERINARY BIOLOGICS MARKET SNAPSHOT 157
FIGURE 41 REVENUE ANALYSIS OF KEY PLAYERS IN VETERINARY BIOLOGICS
MARKET, 2022–2024 232
FIGURE 42 MARKET SHARE ANALYSIS OF KEY PLAYERS IN VETERINARY BIOLOGICS
MARKET (2024) 232
FIGURE 43 US MARKET SHARE ANALYSIS OF KEY PLAYERS IN VETERINARY BIOLOGICS MARKET (2024) 233
FIGURE 44 MARKET SHARE ANALYSIS OF KEY PLAYERS IN VETERINARY DIAGNOSTIC KITS MARKET (2024) 236
FIGURE 45 US: VETERINARY DIAGNOSTIC KITS MARKET SHARE ANALYSIS, 2024 236
FIGURE 46 RANKING OF KEY PLAYERS IN VETERINARY BIOLOGICS MARKET (2024) 238
FIGURE 47 RANKING OF KEY PLAYERS IN VETERINARY DIAGNOSTIC KITS MARKET (2024) 239
FIGURE 48 VETERINARY BIOLOGICS MARKET: COMPANY EVALUATION MATRIX, 2024 240
FIGURE 49 VETERINARY BIOLOGICS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 247
FIGURE 50 VETERINARY BIOLOGICS MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 250
FIGURE 51 EV/EBITDA OF KEY VENDORS 251
FIGURE 52 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 251
FIGURE 53 ZOETIS SERVICES LLC: COMPANY SNAPSHOT 257
FIGURE 54 IDEXX: COMPANY SNAPSHOT 263
FIGURE 55 ELANCO: COMPANY SNAPSHOT 270
FIGURE 56 MERCK & CO., INC.: COMPANY SNAPSHOT 274
FIGURE 57 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT 278
FIGURE 58 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT 281
FIGURE 59 NEOGEN CORPORATION: COMPANY SNAPSHOT 284
FIGURE 60 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT 287
FIGURE 61 IMMUCELL CORPORATION: COMPANY SNAPSHOT 289